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Abstract 
 
Segmentation defects of the vertebrae (SDV) are caused by aberrant somite formation during 
embryogenesis and result in irregular formation of the vertebrae and ribs. The Notch signal 
transduction pathway plays a critical role in somite formation and patterning in model vertebrates. 
In humans, mutations in several genes involved in the Notch pathway are associated with SDV, with 
both autosomal recessive (MESP2, DLL3, LFNG, HES7) and autosomal dominant (TBX6) inheritance. 
However, many individuals with SDV do not carry mutations in these genes. Using whole-exome 
capture and massive parallel sequencing, we identified compound heterozygous mutations in 
RIPPLY2 in two brothers with multiple regional SDV, with appropriate familial segregation. One novel 
mutation (c.A238T:p.Arg80*) introduces a premature stop codon. In transiently transfected C2C12 
mouse myoblasts, the RIPPLY2 mutant protein demonstrated impaired transcriptional repression 
activity compared with wild-type RIPPLY2 despite similar levels of expression. The other mutation 
(c.240-4T>G), with minor allele frequency <0.002, lies in the highly conserved splice site consensus 
sequence 5' to the terminal exon. Ripply2 has a well-established role in somitogenesis and vertebral 
column formation, interacting at both gene and protein levels with SDV-associated Mesp2 and Tbx6. 
We conclude that compound heterozygous mutations in RIPPLY2 are associated with SDV, a new 
gene for this condition. 
  
Introduction 
Congenital vertebral malformation is a relatively common disorder, with an incidence of 0.5–1 per 
1000 live births (1). Vertebral defects may be seen in combination with defects in other organs or 
tissues (syndromic), or may occur in isolation (non-syndromic). One important sub-class of vertebral 
defects is segmentation defects of the vertebrae (SDV). SDV arises from incorrect formation of the 
vertebral precursors (somites) during early embryogenesis. Somite formation (somitogenesis) occurs 
via a complex interplay of signal transduction pathways and transcriptional regulators (2). The Notch 
signal transduction pathway is of particular importance in this process, and individual mutations of 
Notch pathway components have been associated with a variety of phenotypes in both humans and 
mice, including vertebral fusion, hemi-vertebrae, and proximal fusions or bifurcations of the ribs. 
The International Consortium for Vertebral Anomalies and Scoliosis (ICVAS) recently developed a 
standardized nomenclature (3), broadly dividing SDV according to the presence of single or multiple 
vertebral anomalies. The multiple anomalies group is further subdivided into regional (e.g. cervical, 
lumbar, sacral, etc.) or more generalized (with ≥10 contiguous malformed vertebrae) forms. This 
latter group includes spondylocostal dysostosis (SCD). Of note, milder forms of SDV are sometimes 
referred to as congenital scoliosis. 
 
Over the past 15 years, the genetic causes of SDV have been intensively examined. Many cases 
appear to be Mendelian, typically with autosomal recessive inheritance although autosomal 
dominant inheritance has also been described. In the case of the SCD subgroup, the majority of 
recessive cases are caused by homozygous or compound heterozygous mutations of the Notch 
ligand DLL3 (4,5). Other causes of recessive SCD include compound heterozygous or homozygous 
recessive mutations of LFNG (a modifier of NOTCH receptor activity (6)), and the transcription 
factors MESP2 (7) and HES7 (8) (both direct targets of Notch signalling). We recently demonstrated 
that mutation of another direct target of Notch signalling, TBX6 (9), caused dominant SCD in multiple 
individuals in one family (10). Lastly, a milder form of SDV (Klippel–Feil syndrome) is associated with 
autosomal recessive mutations in MEOX1 (11,12) and variably penetrant autosomal dominant 
mutations in GDF3 and GDF6 (13,14). 
 
Interestingly, we have also shown that individuals with heterozygous mutations in either MESP2 or 
HES7 are predisposed to developing a milder SDV phenotype (congenital scoliosis). Further, mouse 
embryos heterozygous for mutations in any of several Notch signalling pathway genes (Hes7, Mesp2, 
Notch1 or Dll1) had a significantly increased prevalence and severity of vertebral defects after 
exposure to short-term gestational hypoxia during somitogenesis (15). Thus, both the penetrance 
and severity of SDV may be affected by gene–environment interactions. 
 
Here we have used whole-exome sequencing to identify compound heterozygous mutations in 
RIPPLY2 in two brothers with SDV. 
Results 
Clinical information 
 
We identified two brothers with SDV (SKDP-10.3 and SKDP-10.4) born to healthy, non-
consanguineous parents of Caucasian background. SKDP-10.3 had failure of formation of the 
posterior elements of C1–C4 with descent of the occipital bone, resulting in canal stenosis and cord 
compression (Fig. 1A–C). He also had hemivertebrae and butterfly vertebrae between T2 and T7, 
resulting in a mild thoracic scoliosis (Fig. 1D). His brother, SKDP-10.4, had deficiency of the posterior 
elements of C1–C3, left hemivertebrae at C4 and T9, and a right hemivertebra at T4 (Fig. 1E and F), 
causing marked cervical kyphosis at the C2/C3 level with associated cord compression. According to 
ICVAS nomenclature (3), the vertebral malformation in these brothers would be classified as M-SDV-
RU (multiple segmentation defects of the vertebrae, regional, unidentified). Spinal abnormalities 
were excluded in both the father (SKDP-10.1) and the brothers' healthy sister (SKDP-10.5) by 
conventional radiographs. The mother (SKDP-10.2) was thought to have a possible C5 spina bifida 
occulta on plain radiographs but computerized tomography did not confirm this finding. Spinal 
radiographs of the maternal grandfather (SKDP-10.201) and grandmother (SKDP-10.202) were 
normal. The siblings had previously tested negative for mutations in DLL3, MESP2, LFNG, and HES7. 
 
Figure 1. 
 
 
Whole-exome sequencing 
Whole-exome capture and massive parallel sequencing was performed using DNA from both 
affected boys, their unaffected sister and their unaffected parents. Given the population frequency 
of SDV, sequencing results were filtered conservatively to exclude variants with minor allele 
frequency (MAF) >0.01 observed in NCBI dbSNP (release 135), 1000Genomes(16), 1000Genomes 
small indels (called using the DINDEL programme (17), 46Genomes release by Complete Genomics, 
and other whole exomes from over 1200 control samples run internally using similar capture 
technology. The data were further filtered empirically for compound heterozygous variant 
segregation, to fit the suspected disease segregation in this non-consanguineous family and the 
usual pattern of recessive inheritance in SDV (Table 1). 
Table 1. 
 
Compound heterozygous mutations were identified in only one gene, RIPPLY2, a gene with an 
established role in somitogenesis (discussed below). Appropriate segregation in the extended 
pedigree was confirmed by Sanger sequencing (Fig. 2). One previously unreported mutation, in exon 
3 (c.A238T:p.Arg80* [NM_001009994]) introduces a stop codon in a highly conserved region 
(Genomic Evolutionary Rate Profiling [GERP] (18) score of 3.02). This mutation was predicted to be 
highly deleterious using the protein functional prediction algorithms MutationTaster (19) and SIFT 
(20). The stop codon results in the loss of 49 carboxy-terminal amino acids, which includes the highly 
conserved Ripply homology domain required for direct protein–protein interaction with the T-box 
domain of TBX6 (discussed below) (21). The other mutation is a rare (MAF < 0.002) single base 
substitution in the 5′ predicted splice acceptor site for exon 4 (NM_001009994 [c.240-4T>G]). This 
mutation lies in a string of six highly conserved bases immediately 5′ of the exon 4 start site, with 
conservation at the −4 nucleotide back to zebrafish (22) (GERP score 5.53) and is predicted by both 
the Variant Effect Predictor (VEP V76) (23) and the Human Splicing Finder (24) to affect a splice 
acceptor consensus sequence. 
Figure 2. 
 
For robustness, the data were also analyzed for a homozygous inheritance; for autosomal dominant 
inheritance with gonadal mosaicism (the presence of a heterozygous variant carried by the affected 
brothers but not by their parents or unaffected sister); and for X-linked recessive inheritance (an X-
chromosome variant present in the brothers, with heterozygous carriage in the mother (and possibly 
the unaffected sister) but not in their father). After filtering as described, no variants fitting these 
inheritance patterns were identified. Variants in all previously identified SDV genes were also 
assessed; no coding or splice site mutations were identified in any of the genes previously reported 
to be associated with SDV (DLL3, LFNG, MESP2, HES7, TBX6, MEOX1, GDF3 and GDF6). Lastly, CREST 
(25) and ExomeDepth (26) did not identify copy number variation affecting RIPPLY2. 
Functional analysis of premature stop mutation 
 
In general, a spliced mRNA transcript containing a premature stop codon >50–55 nucleotides 
upstream of an exon–exon junction is degraded by the nonsense-mediated decay (NMD) machinery 
(27). In our case, the premature stop codon is located within 2 nucleotides of the exon 3 splice 
acceptor site. Therefore, this premature stop codon is not likely to trigger NMD, and a truncated 
protein is likely to be produced. 
 
To determine the functional consequences of the c.A238T:p.Arg80* variant, we modified a 
previously published in vitro cell culture system (28) to compare the activity of wild-type and mutant 
RIPPLY2 proteins on Tbx6-mediated transcriptional activation. In transiently transfected C2C12 
mouse myoblasts, expression of wild-type RIPPLY2 protein caused a 50% reduction in reporter 
transcription level compared with control (Fig. 3A, compare lanes 1 and 2). In contrast, the 
transcriptional repression activity of the mutant RIPPLY2 protein was significantly reduced (P<0.01) 
(Fig. 3A, compare lanes 2 and 3). 
Figure 3. 
 
The impaired function of the mutant RIPPLY2 protein could be due to alteration of its translation 
efficiency or protein stability. We investigated the relative expression levels of wild-type and mutant 
protein in cell culture using an in-house expression assay. A strong band was detected in extracts 
from cells transfected with the wild-type construct (Fig. 3B, lane 1). This band was slightly larger 
than the predicted size of 15.5 kDa, perhaps suggesting that the RIPPLY2 protein is post-
translationally modified. In contrast, extracts from cells transfected with RIPPLY2 R80* construct 
contained a weaker doublet band (Fig. 3B, lane 2). Again this was slightly larger than the expected 
size (9.6 kDa). There was no statistical difference in the transcript levels of wild-type and mutant 
RIPPLY2 (data not shown). We therefore conclude that the p.R80* form of RIPPLY2 has reduced 
transcriptional repressor activity, due to reduced protein stability, loss of 49 carboxy-terminal amino 
acids, or both. 
Functional analysis of splice site mutation 
 
The c.240-4T>G mutation affected the upstream acceptor splice site for the terminal exon of 
RIPPLY2. We developed a qPCR assay to compare relative mRNA amplification across the exon 1/2 
junction and exon 3/4 junction, optimized successfully using the full-length cDNA clone of human 
RIPPLY2 (Supplementary Material, Fig. 1A and B). However, we were unable to detect expression of 
RIPPLY2 in peripheral blood mononuclear cells, bone or buccal mucosal cells, from healthy controls 
or from affected and unaffected family members, despite robust expression of housekeeping genes 
RPL132 and β-ACTIN (Supplementary Material, Fig. 2A and B). We also trialled commercial TaqMan® 
gene expression assays for RIPPLY2 with identical results (not shown). Thus, we were unable to 
prove a functional effect of the observed splice site mutation. Given that Ripply2 expression appears 
to be restricted to embryogenesis these results were not unexpected. One could hypothesize that 
disruption of the acceptor splice site mutation may result in abnormally spliced mRNA that would be 
degraded due to the lack of polyadenylation. 
Mouse model and gene–environment interaction study 
 
We have previously shown that some cases of SDV might be due to a combination of 
haploinsufficiency for a NOTCH pathway gene and an environmental factor (15). Although we 
identified appropriately segregating compound heterozygous mutations in RIPPLY2, it is formally 
possible that only one of these alleles has generated the phenotype in combination with an 
environmental influence. In the mouse, no phenotype has been reported for heterozygous embryos 
carrying a null Ripply2 allele (29,30). However, we have previously identified vertebral defects, with 
variable penetrance and severity, in embryos heterozygous for null alleles of other NOTCH pathway 
genes involved in somitogenesis, although such heterozygotes were originally reported as having no 
phenotype (15). In the same study, we also identified a gene–environment interaction between 
NOTCH pathway genes and short-term gestational hypoxia that results in an increased penetrance 
and severity of SDV (15). We therefore examined more extensively the vertebral phenotype of E14.5 
embryos heterozygous for the null Ripply2 allele (Ripply2TM1.1Ysa30) with and without exposure to 
short-term gestational hypoxia. 
 
Ripply2+/− male mice were mated with C57BL/6J females to generate litters carrying both wild-type 
and heterozygous embryos. Embryos were collected at embryonic day E14.5, and their developing 
skeletons examined following alcian blue staining. Without exposure to hypoxia, 1/33 heterozygous 
embryos had a slight vertebral defect (a unilateral interruption of the lamina of S1), whereas 40/40 
wild-type embryos were normal. Thus loss of one allele of Ripply2 did not cause vertebral defects 
with significant penetrance. Pregnant mice were also exposed to short-term mild hypoxia (8% 
oxygen for 8 h at E9.5 followed by return to normoxia until E14.5) as these conditions have led to 
increased penetrance and severity of vertebral defects in mice heterozygous for other genes 
associated with SDV (Mesp2, Hes7) (15). Here, 4/30 heterozygous embryos had mild defects, each 
involving only a single vertebra, compared with 1/35 wild-type embryos. Thus hypoxia did not 
significantly increase the penetrance or severity of vertebral defects observed in Ripply2+/− embryos 
(P = 0.15, one-tailed Fisher's exact test). 
 
These results suggest that the vertebral phenotype of the human patients is due to compound 
heterozygote mutations in RIPPLY2, rather than a combination of haploinsufficiency and an 
environmental influence. 
Discussion 
 
We have identified rare compound heterozygous mutations in RIPPLY2 in affected individuals of a 
family with multiple regional SDV. 
 
Ripply2 has been studied extensively in mice and is required for somite segmentation and the 
establishment of rostrocaudal patterning of somites (29,30). Mice homozygous null for Ripply2 have 
severe vertebral and rib malformations, and die perinatally. The vertebral phenotype observed in 
the Ripply2 null mouse resembles the affected individuals in the family presented here: in these 
mice “the metameric pattern of vertebral bodies, intervertebral discs, and neural arches was 
severely disrupted … the symmetry about the left right axis was lost.”(29). By contrast, the 
heterozygous mice did not demonstrate any phenotype; similarly, imaging studies of the 
heterozygous individuals in the family presented here were normal. The similarity in phenotype 
supports our finding that the mutations of RIPPLY2 are likely to be causative of SDV in this family. It 
also demonstrates the excellence of the mouse model in the study of congenital vertebral 
malformation in humans. At least 50 genes are required in the mouse for normal somite formation; 
these are therefore plausible candidate genes for SDV in humans (31). 
 
The phenotype of homozygous null Ripply2 mice is also very similar to mice homozygous null for the 
autosomal recessive SCD genes Dll3, Mesp2, Lfng and Hes7 (31) All SCD-causing genes identified in 
humans to date are expressed in the presomitic mesoderm of the mouse embryo and encode 
proteins that are either part of the Notch signal transduction pathway [DLL3 (4), LFNG (6)] and/or 
are direct target genes of NOTCH1 signalling (Mesp2 (7), Hes7 (8), Tbx6 (10). Somitogenesis relies on 
a complex series of molecular interactions, and SCD-causing genes illustrate this: the DLL3 protein is 
an inhibitory ligand of NOTCH1 (32); the LFNG protein affects signalling by glycosylating NOTCH1 
(33); the HES7 protein inhibits transcription of Lfng and Hes7 and in doing so periodically inhibits 
NOTCH1 signal transduction (34); and the TBX6 protein activates the expression of the Hes7 gene 
(35). 
 
Members of the Ripply family of proteins are negative regulators of T-box proteins (which include 
TBX6, coded by another known SCD gene 10), converting them from transcriptional activators to 
repressors (21). Ripply proteins simultaneously bind to the DNA binding domain of T-box proteins 
(via their Ripply homology domain) (21), and to Groucho/TLE transcriptional corepressor proteins 
(via the highly conserved tetrapeptide WRPW motif in their amino terminal region) (36). In the 
mouse, Ripply2 is expressed in the rostral presomitic mesoderm in a domain partially overlapping 
another transcription factor, Mesp2 (29,30,36,37). Ripply2 is a direct transcriptional target of Mesp2 
protein and the T-box protein Tbx6 (30,38,39). In turn, Ripply2 protein forms a negative feedback 
loop by repressing Tbx-mediated transcription from the Mesp2 promoter (21,30,40). Ripply proteins 
are highly conserved in all vertebrates, and in addition to their role in patterning the somites are also 
important for the development of the pharyngeal apparatus and pre-placodal ectoderm (30,41,42). 
Mutations in RIPPLY2 have not been reported in human disease previously; and variants in this gene 
are uncommon. From our own internal data of 991 samples with unrelated disorders sequenced 
using similar technology, no individual had compound heterozygous variants in RIPPLY2. Seven 
individuals carried a variant in RIPPLY2 with MAF < 0.05. Of these, four were non-coding and two 
had MAF 0.01–0.05 (i.e. unlikely to be pathogenic given their frequency). One individual had a rare 
variant in RIPPLY2 (MAF < 0.001). Thus the frequency of rare (MAF < 0.01) coding variants in RIPPLY2 
is 1/1982; the probability of two rare (MAF < 0.01) variants in RIPPLY2 occurring by chance is 2.54 × 
10−7. The probability of both segregating appropriately in this family is even lower. 
 
We have demonstrated the functional consequence of the novel stop mutation (c.A238T:p.Arg80*). 
We were unable to demonstrate a functional consequence of the mutation affecting the terminal 
exon splice site consensus sequence (c.240-4T>G) due to its location and the (likely) restriction of 
Ripply2 expression to embryogenesis. This mutation affects a highly conserved base in the splice site 
consensus sequence predicted by two algorithms to be damaging; further, the mutation interrupts 
the usual splice site pattern whereby the terminal AG of the splice site motif is preceeded by a 
polypyrimidine tract (43) by replacing the usual pyrimidine (T) with a purine (G):of note, in 
Caenorhabditis elegans, replacing the −4 mRNA base (U) with G results in the greatest disruption to 
binding for any substitution at this position (44). Thus this mutation is highly likely to have functional 
consequence also. 
 
Exome sequencing has proven a highly fruitful means of gene discovery (45). Here we have used this 
technology to identify extremely rare compound heterozygous damaging mutations in highly 
conserved bases in RIPPLY2, with appropriate segregation in the family. Our findings are highly 
plausible, especially given the known role of RIPPLY2 in somitogenesis and the phenotypic overlap 
with the Ripply2 null mouse. Further we have shown functional consequences of the coding 
mutation. We acknowledge that we were unable to prove a functional consequence of the splice site 
mutation. We also do not have another affected family replicating these genetic findings and thus 
we are reporting association rather than established causation. However, the data presented above 
provides strong evidence that the identified mutations in RIPPLY2 are the cause of SDV in this family. 
These are the first reported cases of a human disease caused by mutations in this gene. This work 
extends the spectrum of human diseases associated with mutations in the Notch pathway. 
Materials and Methods 
Clinical samples 
 
This study was approved by University of Queensland Human Research Ethics Committee (approval 
ID 2011000876) and all participants or their legal guardians gave informed written consent. DNA was 
extracted from peripheral blood mononuclear cells by conventional chloroform methods. Salivary 
samples were also obtained from all family members for expression studies. A bone sample was 
obtained from SKDP-10.3 at the time of spinal surgery, with subsequent cDNA extraction as 
described below. 
Exome sequencing 
 
Sequencing libraries were constructed from 1.6 µg genomic DNA using the Illumina TruSeqDNA 
sample preparation kit. Libraries were combined in pools of six for target capture using the Illumina 
TruSeq Exome Enrichment Kit. Libraries were assessed pre- and post-capture for both quality and 
yield using the Agilent High Sensitivity DNA assay and KAPA Library Quantification Kit. Massively 
parallel sequencing was performed using the Illumina HiSeq2000 to generate 100 bp paired-end 
reads (2 × 100PE). Twelve samples were run per flow cell lane using version 3 SBS reagents. 
 
Sample demultiplexing, initial base calling, alignment and variant identification were performed as 
described previously (46). Summary statistics for mapping and coverage are presented in 
Supplementary Table 1. 
Functional analysis of STOP mutation 
 
We modified a previously published in vitro cell culture system (28) to compare the activity of wild-
type and mutant RIPPLY2 proteins on Tbx6-mediated transcriptional activation. We obtained a full-
length cDNA clone of human RIPPLY2 (Open Biosystems clone 40146491), and PCR amplification was 
used to transfer the full cDNA into the expression vector pCMX (47). The p.R80* mutation was 
introduced into this construct using PCR-based site-directed mutagenesis. Transcription assays were 
performed in mouse muscle satellite C2C12 cells (48,49) grown in high-glucose DMEM (Life 
Technologies) containing 10% FCS (Life Technologies). Transfections were performed using 
Lipofectamine® LTX and PLUS™ reagent (Life Technologies) in 12-well trays. Cells were cotransfected 
with plasmids encoding wild-type or mutant RIPPLY2; a mouse Tbx6 expression plasmid (28); and 
firefly (pGL3-P2Ewt 28) and Renilla (SV40 promoter) luciferase reporters. Cells were harvested in 250 
µl of Passive Lysis Buffer (Promega) 24 h after transfection. Firefly and Renilla luciferase activities 
were assayed using the Dual-Luciferase reporter system (Promega) and measured on a FLUOstar 
Optima Luminometer (BMG). Firefly luciferase counts were normalized against Renilla luciferase 
counts to account for differences in transfection efficiency. Assays were performed in triplicate. 
One-way analysis of variance was performed on data from four independent experiments, and 
significance was determined using Tukey's post hoc test. 
Relative expression levels of wild-type and mutant protein in cell culture 
 
As no commercial RIPPLY2 antibody was available, we added an in-frame HA tag to the amino-
terminus of both wild-type and mutant RIPPLY2 constructs. These were transfected into C2C12 cells 
and harvested 24 h later. Western blot analysis was performed using mouse monoclonal anti-HA 
(Covance) and goat anti-beta tubulin (Abcam) primary antibodies, with IRDye 800 Donkey anti-
mouse (LI-COR Biosciences) and AlexaFluor 680 Donkey anti-goat (Invitrogen) secondary antibodies. 
Blots were imaged using an Odyssey Infrared Imaging System (LI-COR Biosciences). 
 
To ensure efficient transcription of the construct, we compared transcript levels of wild-type and 
mutant plasmids using RT-qPCR. Two biological replicates of C2C12 cells were transfected with 
expression constructs encoding wild-type or mutant RIPPLY2 or a control unrelated protein. RNA was 
extracted 24 h later using PureLink RNA kit (Life Technologies), reverse transcribed using Superscript 
III VILO cDNA synthesis kit (Life Technologies), and analyzed by qPCR using FAM labelled 
Hs00956565_g1 (RIPPLY2) and VIC labelled Mm01205647_g1 (β-actin) TaqMan probes (Life 
Technologies) on a 480 LightCycler (Roche). 
Functional analysis of splice site mutation 
 
RNA from affected and unaffected family members and healthy controls was extracted from 
peripheral blood mononuclear cells, bone and saliva using the Qiagen RNeasy Mini kit (Qiagen, Cat 
no. 74106), Trizol extraction and Oragene RNA purification protocol respectively. cDNA was 
synthesized using the Invitrogen SuperScript® III First strand synthesis system (Life Technologies 
18080-051) and qPCR was performed using Invitrogen SYBR Select Master Mix (Life Technologies, 
Cat no. 4472908) and primers designed to amplify Exon 1–2 and Exon 3–4 of the RIPPLY2 transcript 
(primers available on request). TaqMan® gene expression primers (Hs00956565_g1 RIPPLY2, 
hCG401131; Hs00956567_m1 : RIPPLY2, hCG401131) targeting exons 1–2 and 3–4 of RIPPLY2 
respectively, were also used, with TaqMan® Gene Expression Master Mix (Life Technologies, Cat no. 
4369016) to investigate differential expression of the full length RIPPLY2 transcript in affected and 
unaffected family members. The previously listed full-length cDNA RIPPLY2 clone was used to 
optimize all primer sets. Primers for human ribosomal protein L32 (RPL32) and Taqman gene 
expression primers for human B-actin (ACTB) were used as housekeeping gene controls in qPCR 
assays (primers available upon request). 
Mice and exposure to short-term gestational hypoxia 
 
Animal experiments were performed in accordance with institutional and national guidelines and 
regulations with the approval of the Garvan Institute of Medical Research/St Vincent's Animal 
Experimentation Ethics Committee, Sydney, Australia (approval number 12/33). Mice, heterozygous 
for the null Ripply2 allele (Ripply2TM1.1Ysa) were maintained on a C57BL/6J background and 
genotyped as described (30). 
 
C57BL/6J females were mated with Ripply2+/− male mice. Gestation continued under normal 
atmospheric conditions (21% oxygen) until embryos were harvested at embryonic day E14.5 and 
their developing skeletons were stained using alcian blue as described (15). Alternatively, pregnant 
C57BL/6J mice were exposed to lowered oxygen levels at normal atmospheric pressure on E9.5 as 
described (15). The oxygen sensor was calibrated prior to each experiment to provide a constant 
oxygen level ±0.2%. The oxygen level was reduced to 8% over a 20 min period, the mice exposed for 
8 h, and at the end of the exposure the mice were gradually returned them to normoxia over a 20 
min period. Embryos were harvested at E14.5. 
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Figure 1 
 
Clinical images of affected individuals. (A–C) 3D-CT of SKDP-10.3 aged 15 months, showing failure of 
formation of the posterior elements of C1 to C4 with descent of the occipital bone, resulting in canal 
stenosis and cord compression. (D) AP radiograph of SKDP-10.3 aged 12 months, showing 
hemivertebrae and butterfly vertebrae situated between T2 and T7, resulting in a mild thoracic 
scoliosis. (E and F) 3D-CT of SKDP-10.4 aged 3 years, showing complex craniocervical anomaly with 
deficiency of the posterior elements of C1– C3, left hemivertebrae at C4 and T9 and right 
hemivertebra at T4. 
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Figure 2. Pedigree showing segregation of RIPPLY2 variants in Family SKDP-10. Red stars indicate 
individuals in whom whole-exome sequencing was performed 
 
 
